



CIN No. : L24239DL2004PLC125888

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2025-26/05

May 14, 2025

**To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051**

**To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai - 400 001**

Symbol: AKUMS

Scrip Code: 544222

Sub: Report of CRISIL Ratings Limited, Monitoring Agency

Respected Sir/Madam,


Pursuant to the regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith the report of CRISIL Ratings Limited, Monitoring Agency dated May 14, 2025 in respect of utilization of proceeds of Initial Public Offer of the company for the quarter ended March 31, 2025.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



Monitoring Agency Report
for
Akums Drugs and Pharmaceuticals Limited
for the quarter ended
March 31, 2025

CRL/MAR/GDS655/2024-25/1385

May 14th 2025

To

Akums Drugs and Pharmaceuticals Limited

304 Mohan Place LSC

Saraswati Vihar,

Delhi-110034

Dear Sir,


Monitoring Agency Report for the quarter ended March 31, 2025 - in relation to the Initial Public Offer ("IPO") of Akums Drugs and Pharmaceuticals Limited ("the Company")

Pursuant to Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**") and Monitoring Agency Agreement dated July 24, 2024, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended March 31, 2025.

Request you to kindly take the same on records.

Thanking you,

For and on behalf of Crisil Ratings Limited



Sushant Sarode

Director, Ratings (LCG)

Report of the Monitoring Agency (MA)

Name of the issuer: Akums Drugs and Pharmaceuticals Limited

For quarter ended: March 31, 2025

Name of the Monitoring Agency: Crisil Ratings Limited

(a) Deviation from the objects: Not applicable


(b) Range of Deviation: Not applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.



Signature:

Name and designation of the Authorized Signatory: Sushant Sarode

Designation of Authorized person/Signing Authority: Director, Ratings (LCG)

1) Issuer Details:

Name of the issuer: Akums Drugs and Pharmaceuticals Limited

Names of the promoter:
a. Sandeep Jain
b. Sanjeev Jain
c. Akums Master Trust

Industry/sector to which it belongs: Pharmaceuticals

2) Issue Details

Issue Period: Tuesday, July 30, 2024, to Thursday, August 1, 2024

Type of issue (public/rights): Initial Public Offer (IPO)

Type of specified securities: Equity Shares

IPO Grading, if any: NA

Issue size: Fresh issuance of Rs 6,800.00 million (Refer Note 1)

Note 1 :

Particulars	Amount as per the Prospectus (Rs. in million)
Gross Proceeds	6,800.00*
Less: Offer Expenses	426.30**
Net Proceeds	6,373.70

*Crisil Ratings shall be monitoring the gross proceeds.

**As per the Prospectus dated August 01, 2024, the approximate issue related expense is Rs 426.30 million. The issue expenses paid till the quarter ended March 31, 2025 amounts to Rs. 230.39 million with the remaining Rs 195.91 million lying unutilised in the Public Offer account as per the Management Undertaking & Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information/certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Management undertaking, Peer-reviewed Independent Chartered Accountant certificate [^] , Prospectus, Bank Statements	No Comment	No Comment
Whether shareholder approval has been obtained in case of material deviations [#] from expenditures disclosed in the Offer Document?	NA	Management undertaking, Peer-reviewed Independent Chartered Accountant certificate [^]	No Comment	No Comment
Whether the means of finance for the disclosed objects of the issue has changed?	No		No Comment	No Comment
Is there any major deviation [#] observed over the earlier monitoring agency reports?	NA		No Comment	No Comment
Whether all Government/statutory approvals related to the object(s) have been obtained?	NA		No Comment	No Comment
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	NA		No Comment	No Comment
Are there any favorable events improving the viability of these object(s)?	NA		No Comment	No Comment
Are there any unfavorable events affecting the viability of the object(s)?	NA		No Comment	No Comment
Is there any other relevant information that may materially affect the decision making of the investors?	NA		No Comment	No Comment
<p>[#] Where material deviation may be defined to mean: -</p> <p>(a) Deviation in the objects or purposes for which the funds have been raised.</p> <p>(b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.</p>				

NA represents Not Applicable

[^]Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

4) Details of object(s) to be monitored:

i. Cost of the object(s):

Sr. No.	Item Head	Source of information/certification considered by MA for preparation of report	Original cost (as per the Offer Document) (Rs in million)	Revised Cost (Rs in million)	Comment of the Monitoring Agency	Comments of the Board of Directors		
						Reason of Cost revision	Proposed financing option	Particulars of firm arrangements made
1	Repayment/prepayment of indebtedness of the Company	Management undertaking, Peer-reviewed Independent Chartered Accountant certificate [^] , Prospectus	1,599.10	NA	No revision	No Comment		
2	Repayment/prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited		2,270.90	NA	No revision	No Comment		
3	Funding incremental working capital requirements of our Company		550.00	NA	No revision	No Comment		
4	Pursuing inorganic growth initiatives through acquisitions		278.70	NA	No revision	No Comment		
5	General corporate purposes (GCP)*		1,675.00	NA	No revision	No Comment		
Total			6,373.70	-	-	-		

[^]Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

*The amount utilised for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1,700.00 million) from the Fresh Issue.

ii. Progress in the object(s):

Sr. No.	Item Head#	Source of information/certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document (Rs in million)	Amount utilized (Rs in million)			Total unutilized amount (Rs in million)	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter	During the quarter	At the end of the quarter			Reasons for idle funds	Proposed course of action
1	Repayment/prepayment of indebtedness of the Company	Management undertaking, Peer-reviewed Independent Chartered Accountant certificate ^, Prospectus, Bank Statements	1,599.10	1599.10	-	1599.10	0.00	Fully utilised in Sep-24 quarter	No Comment	
2	Repayment/prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited		2,270.90	2,270.90	-	2,270.90	0.00	Fully utilised in Dec-24 quarter	No Comment	
3	Funding incremental working capital requirements of our Company		550.00	0.00	550.00	550.00	0.00	Fully utilised in Mar-25 quarter	No Comment	
4	Pursuing inorganic growth initiatives through acquisitions		278.70	0.00	197.30	197.30	81.40	Refer Note 2	No Comment	
5	General corporate purposes (GCP)		1,675.00	1,675.00	-	1,675.00	0.00	Fully utilised in Dec-24 quarter	No Comment	
Total			6,373.70	5,545.00	747.30	6,292.3	81.40	-	-	

Note 2: In line with the past 3 years material acquisitions, as part of the inorganic growth the company has purchased land & building in Ambernath, Mumbai to set up an R & D division for further expansion of expertise in new/existing product portfolio in synergy with the existing business. Out of the total agreement sale value of Rs 249.50 million the company has paid the first instalment of Rs 197.30 million during the quarter. The second instalment of Rs 52.20 million plus any government charges including but not limited to stamp duty will be paid subsequently.

^ Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

#Brief description of objects:

Object of the Issue	Description of objects as per the offer document filed by the issuer
Repayment/ prepayment of indebtedness of the Company	The Company proposes to utilise an estimated amount of Rs 3,870 million from the Net Proceeds towards repayment/ prepayment of some of the loan facilities availed by the Company and its Subsidiaries ("Identified Loans"). The repayment/ prepayment, will help reduce their outstanding indebtedness, assist in maintaining a favourable debt-equity ratio and enable utilisation of some additional amount from our internal accruals for further investment in business growth and expansion.
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	The Company proposes to utilise an estimated amount of Rs 3,870 million from the Net Proceeds towards repayment/ prepayment of some of the loan facilities availed by the Company and its Subsidiaries ("Identified Loans"). The repayment/ prepayment, will help reduce their outstanding indebtedness, assist in maintaining a favourable debt-equity ratio and enable utilisation of some additional amount from our internal accruals for further investment in business growth and expansion.
Funding incremental working capital requirements of our Company	On the basis of the existing working capital requirements, management estimates and projected working capital requirements, the Board has, pursuant to its resolution dated February 7, 2024, approved the projected working capital requirements for the financial year ended March 31, 2025, and the proposed funding of such working capital requirements of the Company. The requirement is proportionate and variable in nature with the growth of our Company.
Pursuing inorganic growth initiatives through acquisitions	The Company has in the past undertaken several acquisitions and shall continue to evaluate acquisition opportunities in the future that it believes supplement the strategic business objectives and growth strategies. In line with the past practice, The Company intends to pursue opportunities to undertake acquisitions (i) that allow us to enhance our scale and market position; (ii) that allow us to enhance our product portfolio including product category adjacencies by unlocking potential synergy benefits; (iii) to extend the reach to new geographic markets outside India; and (iv) to capture additional revenue opportunities from the existing customer base to improve our margin profile
General corporate purposes (GCP)*	<p>The general corporate purposes include, but are not restricted to:</p> <ul style="list-style-type: none"> (i) meeting fund requirements which our Company may face in the ordinary course of business; (ii) strengthening marketing capabilities and brand building exercises; (iii) meeting ongoing general corporate contingencies; and (iv) business requirements of our Company in the ordinary course of business towards salaries and wages, rent, administration expenses, upgrading our technology and maintenance, payment to creditors, advisory services. <p>The allocation or quantum of utilization of funds towards the specific purposes described above will be determined by the Board of the Company, based on its business requirements and other relevant considerations, from time to time. The management, in accordance with the policies of the Board, shall have the flexibility in utilizing surplus amounts, if any.</p>

iii. Deployment of unutilised proceeds[^]:

S. No.	Type of instrument where amount is invested	Amount invested (in Rs million)	Maturity date	Earnings* (in Rs million)	Return on Investment (%)	Market value as at the end of quarter (in Rs million)
1	Fixed deposit with ICICI Bank	0.70	03-Feb-26	0.0073	6.70%	0.7073
2	Fixed deposit with ICICI Bank	80.70	11-Nov-25	0.93	7.40%	81.63
3	Balance in MA account (Refer Note 3)	0.00	-	-	-	0.00
4	Balance in Public offer account (Refer Note 4)	195.91	-	-	-	195.91
	Total	277.31	-	0.94	-	278.25

Note 3: As at the end of the reported quarter the balance in Monitoring Agency account is Rs 16.91 million which pertains to interest realised from fixed deposit redemption.

Note 4: As at the end of the reported quarter the balance in public offer account is Rs 513.13 million. Out of this, company's share is Rs. 195.91 million pertaining to issue expenses.

The Company has not encumbered any of the aforementioned unutilized funds as lien for any purpose

[^] On the basis of management undertaking and Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

*Monitoring the deployment of Interest Income earned from unutilised issue proceeds does not form part of the scope of Monitoring Agency report.

iv. Delay in implementation of the object(s)[^]:

Object(s)	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the Offer Document	Actual		Reason of delay	Proposed course of action
Pursuing inorganic growth initiatives through acquisitions	Fiscal 25-Rs 278.70 million	Refer Note 5	Refer Note 5	No Comment	

Note 5: As per the prospectus dated August 1st 2024, the Company had proposed to deploy Rs 278.70 million towards the Object of Pursuing inorganic growth initiatives through acquisitions by fiscal 2025. However, the Company has utilized Rs 197.30 million as at the end of fiscal 2025, hence, there is a delay from the estimated schedule of implementation. However, the Prospectus further states that, "In the event that the estimated utilization of the Net Proceeds in a scheduled fiscal year is not completely met, the same shall be utilised in the next fiscal year, as may be determined by our Company, in accordance with applicable laws

[^] On the basis of management undertaking and Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant.

5) Details of utilization of proceeds stated as General Corporate Purpose amount in the offer document:

On the basis of management undertaking and Certificate dated May 9, 2025, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant there is no utilisation towards the object of General Corporate Purpose during the reported quarter.

Disclaimers:

- a) *This Report is prepared by Crisil Ratings Limited (hereinafter referred to as "Monitoring Agency"/"MA"/"CRL"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.*
- b) *This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like Peer-reviewed Independent Chartered Accountants (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.*
- c) *Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.*
- d) *The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.*
- e) *The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.*
- f) *The MA report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRL providing or intending to provide any services in jurisdictions outside India, where it does not have the necessary licenses and/or registration to carry out its business activities referred to above.*
- g) *Access or use of this report does not create a client relationship between CRL and the user.*
- h) *CRL is not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing this report, MA has not taken into consideration the objectives or particular needs of any particular user.*
- i) *It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be a basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).*
- j) *The report comprises professional opinion of CRL as of the date they are expressed, based on the information received from the issuer and other sources considered reliable by CRL. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. The report does not constitute statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions.*
- k) *Neither CRL nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents guarantee the accuracy, completeness or adequacy of the report, and shall not have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. CRL and each aforesaid party disclaims any and all express or implied warranties, including but not limited to any warranties of merchantability, suitability or fitness for a particular purpose or use or use. In no event shall CRL or any aforesaid party be liable to any user for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.*
- l) *CRL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with the preparation of this report. CRL has in place a code of conduct and policies for managing conflict of interest.*

- m) *Unless required under any applicable law, this report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRL.*
- n) *By accepting a copy of this Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of this Report.*